Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score.

Abstract

Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptor-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycle-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.

• Authors: Katja Gwin, Marguerite Pinto, Fattaneh A Tavassoli
• Journal: International journal of surgical pathology (Int J Surg Pathol) Vol. 17 Issue 4 Pg. 303-10 (Aug 2009) ISSN: 1066-8969 [Print] United States
• PMID: 19578051 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Ki-67 Antigen

Topics

• Adenocarcinoma (diagnosis, genetics, metabolism, secondary)
• Adult
• Biomarkers, Tumor (metabolism)
• Breast Neoplasms (diagnosis, genetics, metabolism)
• Cell Proliferation
• Female
• Gene Expression Profiling (methods)
• Humans
• Immunohistochemistry
• Ki-67 Antigen (metabolism)
• Lymph Nodes (metabolism, pathology)
• Lymphatic Metastasis
• Middle Aged
• Neoplasm Recurrence, Local (diagnosis, genetics, metabolism)
• Predictive Value of Tests